A Causative Role for Amylin in Diabetic Peripheral Neuropathy

Description

Three pieces of information lead to the basis for this study: 1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy. 2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes. 3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin. The purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Type-2 diabetes and the extent to which symptoms of peripheral neuropathy are expressed in those subjects. The investigators will be testing this by initially collecting blood and skin biopsy samples from subjects, followed by measuring patient sensation and pain responses to heat, cold, and pressure in the upper extremities.

Conditions

Type2 Diabetes, Peripheral Neuropathy

Study Overview

Study Details

Study overview

Three pieces of information lead to the basis for this study: 1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy. 2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes. 3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin. The purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Type-2 diabetes and the extent to which symptoms of peripheral neuropathy are expressed in those subjects. The investigators will be testing this by initially collecting blood and skin biopsy samples from subjects, followed by measuring patient sensation and pain responses to heat, cold, and pressure in the upper extremities.

A Causative Role for Amylin in Diabetic Peripheral Neuropathy

A Causative Role for Amylin in Diabetic Peripheral Neuropathy

Condition
Type2 Diabetes
Intervention / Treatment

-

Contacts and Locations

Lexington

UK Robert Straus Behavioral Science Laboratory, Lexington, Kentucky, United States, 40508

Lexington

University of Kentucky - Kentucky Neuroscience Institute, Lexington, Kentucky, United States, 40536

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subject has been diagnosed with Type-2 Diabetes.
  • * Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests.
  • * Subject has not been diagnosed with Type-2 Diabetes.
  • * Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Zabeen Mahuwala, MD,

John T Slevin, M.D., M.B.A., PRINCIPAL_INVESTIGATOR, University of Kentucky Department of Neurology

Zabeen Mahuwala, MD, PRINCIPAL_INVESTIGATOR, University of Kentucky

Study Record Dates

2024-12